Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK137647
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules
01
Overview
GSK137647 is a potent, selective, and non-carboxylic acid small molecule agonist of the free fatty acid receptor 4 (FFA4, also known as GPR120). Developed by GSK, it exhibits high selectivity for FFA4 over other free fatty acid receptors (FFA1, FFA2, and FFA3). GSK137647 is widely used as a chemical probe in preclinical research to investigate the physiological roles of FFA4 in metabolic regulation, glucose homeostasis, insulin secretion, and anti-inflammatory pathways. It has been shown to enhance glucose-stimulated insulin secretion in pancreatic beta cells and attenuate inflammatory responses in macrophages and adipocytes.
- Other names
- 4-methoxy-N-(2,4,6-trimethylphenyl)benzenesulfonamide
02
Targets
FFAR4 (Free fatty acid receptor 4)
Beyond the preview
Go deeper on GSK137647.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK137647.